
Claire Mazumdar, Ph.D., MBA
Chief Executive Officer
Bicara Therapeutics
The founding CEO of Bicara Therapeutics, Claire Mazumdar, led business development and corporate strategy at Rheos Medicines, where she supported a major partnership with Roche. As a Senior Associate at Third Rock Ventures, she focused on company formation and supported business development for TRV portfolio companies. She is also a Member of the Board of Directors for Noora Health, a global non-profit which works to improve patient outcomes and strengthen health systems by equipping family caregivers with the skills they need to care for their loved ones.
She holds a Bachelor of Science in Biological Engineering from MIT, earned her MBA from Stanford Graduate School of Business and a Ph.D. in Cancer Biology from Stanford School of Medicine. Her research in tumor immunology and cancer epigenetics has been published in Nature, Cell Stem Cell and Cancer Cell.

Liviu Niculescu, M.D.
Chief Medical Officer
Bicara Therapeutics
Previously Head of Clinical Development for Oncology at bluebird bio
Nine years at Pfizer Pharmaceuticals as Senior Medical Director and nearly seven years as Vice President of Global Medical Affairs at Takeda Oncology
M.D. from the Carol Davila University of Medicine and Pharmacy; master’s degree in Public Health from Harvard University

Glenn J. Hanna, M.D.
Principal investigator from Dana-Farber Cancer Institute
Bicara Therapeutics
Dr. Hanna completed his fellowship training in hematology and medical oncology at Dana-Farber Cancer Institute in 2016. Prior to this, he earned his medical degree from Georgetown University School of Medicine in 2010, where he graduated summa cum laude, a member of Alpha Omega Alpha Honor Society and the Kober Medalist for academic excellence. He joined the faculty of the Center for Head and Neck Oncology in 2017. Dr. Hanna's clinical and translational research efforts are focused on both molecular and immunologic biomarker discovery to foster precision medicine approaches to treat head and neck cancers and improve patient outcomes. He maintains foundation and industry support to explore immuno-oncology approaches to treat head and neck cancers and high-risk oral precancerous lesions using novel combination immune checkpoint blockade, intra-tumoral injectables, and immune effector cell (IEC) therapies. He has additional interest in precision medicine approaches to treat salivary cancers of the head and neck, and in using cell-free DNA to treat and monitor human papillomavirus (HPV)-associated head and neck cancers.